Astellas drops lawsuit against Medicare drug negotiations
Originally Published 2 years ago — by STAT
Astellas has withdrawn its lawsuit against the Biden administration after its drug Xtandi was not selected for Medicare's drug price negotiation program. The company maintains that the program is "bad policy and unconstitutional."